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Small tumor necrosis factor receptor biologics
inhibit the tumor necrosis factor-p38 signalling axis
and inﬂammation
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Carol Haddad1,2,4, Suresh Mahalingam 5, Charles S. Hii1,2 & Antonio Ferrante1,2,6,7
Despite anti-TNF therapy advancements for inﬂammatory diseases such as rheumatoid
arthritis, the burden of diseases remains high. An 11-mer TNF peptide, TNF70–80, is known to
stimulate selective functional responses compared to the parent TNF molecule. Here, we
show that TNF70–80 binds to the TNF receptor, activating p38 MAP kinase through TNF
receptor-associated factor 2. Using truncated TNFR mutants, we identify the sequence in
TNFRI which enables p38 activation by TNF70–80. Peptides with this TNFRI sequence, such as
TNFRI206–211 bind to TNF and inhibit TNF-induced p38 activation, respiratory burst, cytokine
production and adhesion receptor expression but not F-Met-Leu-Phe-induced respiratory
burst in neutrophils. TNFRI206–211 does not prevent TNF binding to TNFRI or TNF-induced
stimulation of ERK, JNK and NF-κB. TNFRI206–211 inhibits bacterial lipopolysaccharide-induced
peritonitis, carrageenan-induced and antigen-induced paw inﬂammation, and respiratory
syncytial virus-induced lung inﬂammation in mice. Our ﬁndings suggest a way of targeting
TNF-p38 pathway to treat chronic inﬂammatory disorders.
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The pleotropic cytokine, tumour necrosis factor alpha(TNF), plays a major role in the pathogenesis of chronicinﬂammatory diseases. Consequently, the treatment of
these diseases, in particular rheumatoid arthritis, Crohn’s disease
and psoriatic arthritis, has been revolutionised by the availability
of anti-TNF biologics such as monoclonal antibodies, e.g.,
inﬂiximab, certolizumab, adalimumab and golimumab or soluble
TNF receptors, e.g., etanercept1. However, the deleterious effects
of neutralising the actions of TNF, including increased suscept-
ibility to infection, remains a major setback for this type of
therapy. Patients with rheumatoid arthritis receiving anti-TNF
immunotherapy have the increased risk of fungal and bacterial
infections, particularly of reactivating latent tuberculosis1–4, as
well as non-melanoma skin cancers5. In paediatric and adult
patients, combination therapy with anti-TNF biologics and other
forms of immunosuppressives increased the risk of other types of
malignancies5,6. Another approach in the treatment of chronic
inﬂammation involves the targeting of the intracellular pathways
used by the TNFR, in particular the p38 MAP kinase (MAPK).
Unfortunately, this approach has encountered a number of major
setbacks, including poor clinical responses and unexpected toxi-
city, resulting in suspension of clinical trials7,8. Thus, alternative
approaches that target TNF and TNF-mediated signalling in
chronic inﬂammatory conditions are needed.
It has previously been reported that short peptides of the TNF
sequence promote different biological effects of the parent TNF
molecule9–11. Of interest was that an 11-mer TNF peptide,
TNF70–80, representing the amino acid sequence 70–80 of the
TNF monomer, primed neutrophils and promoted immunity to
Plasmodium, as well as Mycobacterium bovis, Klebsiella pneu-
moniae and Aspergillus fumigatus in vitro and/or in vivo9–14.
Here, we show TNF70–80 binds to the TNFR and initiates sig-
nalling through TNF receptor-associated factor 2 (TRAF2) and
p38 MAPK, leading to activation of the neutrophil respiratory
burst. Using this information, we have generated peptides from
the TNFRI sequence which interact with TNF70–80 and inhibit its
ability to activate p38 and the respiratory burst. The TNFRI
peptides block the inﬂammatory response in models of auto-
immunity and infection. This provides a basis for developing
cytokine receptor biologics with singular therapeutic potential.
Results
Activation of p38 MAP kinase by TNF70–80 biologic. We have
previously shown that peptides of different regions of the TNF
sequence displayed selective biological properties in vitro and
in vivo compared to the parent TNF molecule9–11. However, we
have no understanding of how the peptide interacts with and
activates cells. Here, we examined whether its stimulatory effects
on the neutrophil respiratory burst is via the TNFR and p38
MAPK, both of which are required for a TNF-mediated
response15. In these experiments, we used TNF and TNF70–80 at
concentrations that we had previously found to enhance neu-
trophil responses9–14. The data demonstrate that in association
with the activation of p38 MAPK, TNF70–80 stimulated the pro-
duction of superoxide in a similar manner to TNF, measured as
lucigenin-dependent chemiluminescence production (Fig. 1a, b).
The TNF70–80-induced respiratory burst response was inhibited
by the p38 inhibitor, SB203580 (Fig. 1c).
To understand how TNF70–80 caused p38 activation, we
examined its interactions with TNF receptors. Since previous
studies have found that TNFRI is coupled to p38 and is required
for the effects of TNF on neutrophils16,17, we focused on TNFRI
in the following investigations. To investigate whether the peptide
acted via cell surface-expressed TNFR, we used the 70Z/3 pre-B
cell line which lacks TNFRs. It has previously been demonstrated
that 70Z/3 cells either do not bind TNF or lymphotoxin, or
respond to TNF unless they have been transfected with
TNFRI18,19. 70Z/3 pre-B cells were incubated with either TNF
or TNF70–80 and the activation of p38 investigated. In these cells,
both TNF and TNF70–80 failed to stimulate the activity of p38
(Fig. 1d). However, when the cells were transfected with vectors
carrying TNFRI, both ligands caused the activation of p38
(Fig. 1d). These data demonstrate that TNF70–80 bound to and
acted speciﬁcally via the TNFR. Evidence was also generated
which showed that labelled TNF70–80 bound to soluble TNFRI
could be competitively displaced with unlabelled TNF70–80
(Fig. 1e). To obtain further evidence that TNF70–80 enhanced
the activity of p38 via a TNFR-mediated proximal signalling
mechanism, we examined responses in HEK 293T cells which had
been stably transfected with an empty vector, wild-type TRAF2 or
a dominant-negative TRAF2 (ΔTRAF2). The data show that
TNF70–80 enhanced the activity of p38 in cells transfected with
either wild-type TRAF2 or an empty vector, but not in those
transfected with ΔTRAF2 (Fig. 1f). This shows that the activation
of p38 by the peptide requires TRAF2.
Development of TNFRI biologics with anti-TNF activity. Our
data raise the tantalising possibility of a new approach to target
the TNFR-p38 signalling pathway for therapeutic purposes if we
are able to identify the region of TNFRI to which TNF70–80 binds.
To achieve this objective, His-tagged truncation mutants of
TNFRI were constructed by deleting the ﬁrst (M1) or all four
(M4) cysteine-rich domains (CRD) on the extracellular portion of
TNFRI (Fig. 2a). Then, 70Z/3 pre-B cells lacking TNFR18,19 were
transiently transfected with wild-type (WT) or a mutant of
TNFRI. After 24 h, the cells were treated with either diluent or
TNF70–80 (10 μM) and p38 activity assayed. The data showed that
TNF70–80 caused ~2.5-fold increase in p38 activity in WT TNFRI-
and M1 TNFR1-transfected cells and this effect was retained,
albeit appearing reduced (p= 0.11, n= 3, two-sided t test), in
cells transfected with the M4 TNFRI mutant (Fig. 2b).
Since the M4 mutant contains three remnant amino acid
residues, GTT (TNFRI209–211), of the extracellular portion of
TNFRI (Fig. 2c), our data imply that these residues represent the
minimum region in TNFRI to which TNF70–80 binds and is
required by TNF70–80 for activating p38. This therefore raised the
possibility that peptides of this region might also block the
function of TNF70–80. Thus, peptides corresponding to
TNFRI209–211 were made and examined for ability to inhibit
TNF70–80-induced respiratory burst in neutrophils using a
lucigenin-based chemiluminescence (CL) assay. The ﬁrst peptide,
ΔHM4 (LKPGTT) (Fig. 2), composed of a three amino acid
restriction enzyme linker sequence, LKP, that was introduced to
couple the hexahistidine tag to the truncated TNFRI mutants and
TNFRI209–211 (GTT) was synthesised and shown to cause a dose-
dependent suppression in the ability of TNF70–80 to stimulate CL
production in human neutrophils (Fig. 2d, e).
Having obtained the above results with ΔHM4, it was
important to exclude an effect due to the three linker amino
acids. We therefore synthesised and tested the effect of
TNFRI209–211 (GTT) on TNF-induced neutrophil CL production.
Treating TNF with TNFRI209–211 compared to a control peptide
(TGT) caused a dose-dependent inhibition of TNF-induced CL
and an IC50 of 123 μM (Fig. 3a, c). A longer peptide,
TNFRI206–211 (EDSGTT), that contained the three residues N-
terminal to TNFRI209–211 but not the corresponding scrambled
peptide, GEDTST, was effective at inhibiting TNF-induced CL
production with an IC50 of 171 μM (Fig. 3b, d). These data
demonstrate that the minimal TNFRI peptides, revealed by the
above TNF70–80–p38 activity studies, were able to inhibit this
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function of TNF. In addition, we found that extending the
sequence to include residues 198–211 of TNFRI (TNFRI198–211)
(QIENVKGTEDSGTT) increased the anti-TNF action (IC50 of
50 μM) (Fig. 3e). The speciﬁcity of these receptor peptides was
further supported by the ﬁnding that neither TNFRI209–211
(Fig. 3f) nor TNFRI206–211 (Fig. 3g) inhibited fMLF-stimulated CL
production. Previously, we have demonstrated that neutrophil
priming and activation of the respiratory burst by conditioned
medium from Staphylococcus aureus-stimulated mononuclear
leukocytes is due to TNF20. Treatment of the TNF-rich medium
with either TNFRI206–211 or TNFRI209–211 also inhibited the
neutrophil response with IC50 of 216 μM and 146 μM, respec-
tively (Fig. 3h, i). A D-amino form of TNFRI206–211 was also an
effective inhibitor of the TNF-induced CL response with an IC50
of 51 μM (Fig. 3j). Incubation with the peptides alone neither
increased nor decreased the baseline CL in all experiments.
The receptor peptides showed binding to both TNF70–80 and
TNF (Fig. 4a, b). To gain further evidence for the speciﬁcity of the
above-described membrane proximal TNFRI peptides as anti-
TNF agents, we also investigated whether peptides derived from
the CRD of TNFRI, CDR 1, 2 and 3, were able to block the TNF-
induced respiratory burst. The data show that these peptides, in
contrast to the peptides in Fig. 3, did not affect the action of TNF
(Fig. 4c), thus demonstrating their speciﬁcity.
Inhibition of the inﬂammatory response. Apart from inhibiting
the TNF-induced neutrophil oxygen radical production, the
TNFRI peptides inhibited TNF-induced complement receptor
type 3 (CD11b/CD18) upregulation in neutrophils (Fig. 5a–c) and
TNF-induced neutrophil IL-1β and IL-8 production (Fig. 5d).
These effects are indicative of the receptor peptide being an anti-
inﬂammatory agent. We thus sought to examine its effects in
in vivo inﬂammatory responses in mice.
The inﬂammatory reaction, number of inﬁltrating leukocytes
and neutrophils, induced by the intraperitoneal (i.p.) injection of
bacterial LPS was inhibited by TNFRI206–211 (Fig. 6a, b). Similar
inhibition was seen in a chronic inﬂammation model induced by
sheep red blood cell antigens (Fig. 6c) and an acute inﬂammation
model of carrageenan-induced paw inﬂammation in mice
(Fig. 6d).
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Fig. 1 TNF70–80 activates p38 via the TNFRI. Neutrophils were treated with the indicated concentrations of either TNF or TNF70–80 and then incubated for
15 min before examining for p38 activation (a) or measuring chemiluminescence (b) over the 45-min period. The TNF70–80 induced chemiluminescence is
inhibited by the p38 pharmacological inhibitor, SB203580. The neutrophils were pre-incubated with SB203580 for 10 min before the addition of TNF70–80.
c TNF70–80 stimulates p38 activity in 70Z/3 pre-B cells, transfected with hTNFR1 (solid bars). Open bars represent mock-transfected cells. d Inhibition of
biotin-labelled TNF70–80 binding to immobilised TNFR1 by unlabelled TNF70–80. e Peptide-TNFR1 binding was conducted as described under 'Methods'.
Four-parameter curve ﬁt yielded an IC50 value of 55 μM. (Inset) Lack of binding of scrambled peptide. The scrambled peptide and unlabelled TNF70–80 were
both tested at 1 mM in the presence of 10 μM biotinylated TNF70–80. f TNF70–80 (10 μM) stimulated p38 activity in HEK 293T cells stably transfected with
either wild-type TNF receptor-associated factor 2 (TRAF2) or an empty vector, but not in those transfected with a dominant-negative TRAF2 (ΔTRAF2).
Results are mean ± s.e.m. of four experiments. Signiﬁcance of difference (two-tailed Mann–Whitney U test): *p < 0.05; **p < 0.01, ***p < 0.001
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The effectiveness of TNFRI206–211 as an anti-inﬂammatory
agent was further demonstrated in an acute respiratory syncytial
virus (RSV)-induced inﬂammatory mouse model21,22. Mice were
treated intranasally (i.n.) with TNFRI206–211 or the respective
scrambled peptide, 1 day prior to an intranasal challenge with 1 ×
106 plaque forming units of RSV, and then 1 and 3 days post viral
challenge. Mice treated with TNFRI206–211 had signiﬁcantly
reduced numbers of leukocytes around the bronchi (Fig. 6e)
and mucus production in the lungs (Fig. 6f) compared with mice
treated with the control peptide. There was also a reduction in
lung epithelial thickness/inﬂammation score (~50%) (scrambled
peptide: 1.83 ± 0.21; TNFRI206–211: 1.0 ± 0.27, mean ± s.e.m. of
ﬁve mice/group, p > 0.05, Mann–Whitney U test) and in the
number of leukocytes around the lung blood vessels (~70%)
(scrambled peptide: 1.8+3 ± 0.40; TNFRI206–211: 0.7 ± 0.2, mean
± s.e.m. of ﬁve mice/group, p > 0.05, Mann–Whitney U test)
although this did not reach signiﬁcance. The anti-inﬂammatory
effects of TNFRI206–211 were further supported by the ﬁndings
that there was a signiﬁcant reduction in lymphocyte numbers
(Fig. 6g) and IFN-γ content (Fig. 6h) in the bronchoalveolar
lavage (BAL) ﬂuid. The TNFR peptide had no effect on IL-4
production (Fig. 6i), suggesting an effect through the inhibition of
the Th1 responses. Neutrophil numbers in the BAL ﬂuid were
also reduced by TNFRI206–211. Neutrophils were detected in BAL
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ﬂuids of ﬁve of six mice treated with the control peptide
compared with only one of six mice treated with TNFRI206–211 (p
< 0.05; one tail Fischer exact test). Interestingly, the anti-
inﬂammatory effects of TNFRI206–211 were associated with a
signiﬁcant decrease in viral load in the lung (Fig. 6j), as in most
cases impaired resistance to microbial pathogens has been
reported in animals and humans treated with anti-
inﬂammatory agents.
TNFRI206–211 selectively inhibits the TNF-p38 axis. The TNFRI
peptides could exert their effects by blocking selectively the ability
of TNF to signal via p38. To investigate this possibility, we pre-
incubated TNF with TNFRI206–211 or scrambled peptide before
adding these to neutrophils or mononuclear phagocytes (Mono-
Mac 6 cells). The data in Fig. 7a, b demonstrate that TNFRI206–211
but not the scrambled peptide prevented TNF from inducing the
activation of p38 in human neutrophils. This effect was repro-
duced in the MonoMac 6 cells (Fig. 7c). It is likely that
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Fig. 3 Inhibition of TNF-induced responses in neutrophils by TNFRI peptides. a, b Inhibition of superoxide production in neutrophils treated with TNF (1 ng/
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TNFR206–211 has selectivity for this pathway because treatment of
another neutrophil agonist, f-Met-Leu-Phe (FMLF) with
TNFR206–211 did not inhibit the ability to activate p38 (Fig. 7d).
To relate this to the effects of the receptor peptide on the
inﬂammatory response, we examined its effect on mouse TNF
acting on mouse WEHI-164 cells. The results demonstrated that
TNFRI206–211 inhibits the activation of p38 in the murine system
(Fig. 7e). These data imply that the peptides exerted their anti-
inﬂammatory effects by blocking TNF signalling via the p38
pathway. Similar treatment of adherent human neutrophils or
HL-60-derived neutrophils with TNF which had been pre-treated
with the receptor peptide did not inhibit the activation of either
the MAP kinases, ERK1/ERK2 (Fig. 7f) and JNK (Fig. 7g), or of
NF-κB, the latter measured by examining the degradation of IκB-
α (Fig. 7h). To investigate whether the TNF bound to
TNFR206–211 was still able to bind to its receptor, we examined
whether the receptor peptide prevented TNF from binding to the
recombinant TNFRI. TNF bound similarly to TNFRI in the
presence and absence of the receptor peptide (Fig. 7i).
Discussion
Data from our previous reports demonstrated the unique biolo-
gical characteristics of the short TNF mimetic peptide, TNF70–80,
in vitro and in vivo10,11. Here, we show that this peptide stimu-
lates the chemiluminescence response in human neutrophils via
the activation of the MAP kinase, p38. Thus, the TNF-derived
peptide stimulated the activation of p38 in the neutrophils and
the chemiluminescence production was inhibited by the phar-
macological p38 inhibitor, SB203580. Activation of p38 by
TNF70–80 occurred via the TNF receptor, since cells lacking the
TNFRI failed to show p38 activation, and TRAF2 was required
for its ability to activate p38. Because these effects on cellular
function are considered to be important elements in the gen-
eration of an inﬂammatory response, we used this peptide
sequence to identify a complimentary region on the TNFR, which
could be used to block the parent TNF molecule from stimulating
these responses.
Using TNFR1-truncated constructs, we were able to identify a
minimal region in TNFRI which supported the activation of p38
by TNF70–80. Interestingly, peptides of this minimal TNFRI
sequence, TNFRI209–211 and TNFRI206–211, exhibited anti-TNF
activity in vitro, as they inhibited the ability of TNF70–80 or TNF
to induce a chemiluminescence response in neutrophils. Peptides
representing other regions of the TNFRI such as those in the CRD
did not inhibit this response. Furthermore, we showed that the
TNFRI biologics could bind to both TNF70–80 and TNF. Further
support for these interactions was obtained by the ﬁnding that the
TNFRI biologics, TNFR209–211 and TNFRI206–211, inhibited TNF-
mediated activation of p38 in both human and murine cells.
These data demonstrate the efﬁcacy and applicability of these
TNFRI biologics to treat inﬂammation induced by a variety of
agents.
In vivo, the TNFRI peptides inhibited LPS-induced peritonitis,
carrageenan and antigen-induced inﬂammation and respiratory
syncytial virus (RSV)-induced lung inﬂammation. The latter is
particularly useful in gauging the actions of the TNFRI peptides,
as both the effects on pathogenesis and susceptibility to the virus
could be monitored. Importantly, treatment with the TNFRI
peptides signiﬁcantly reduced lung viral load, in addition to the
suppression of virus-induced inﬂammation. This is the ﬁrst
demonstration that this new form of anti-TNF therapy has the
potential to be used in the treatment of infection-induced
pathogenesis as well as non-infectious inﬂammatory conditions.
The ability of TNFRI206–211 to bind TNF suggests a possible
mechanism by which the TNFRI peptides exert their anti-TNF
effects. Such an action would prevent TNF from fully engaging
TNFRI, particularly around the region whose sequence is found
in the TNFRI peptides. Consistent with this idea, it was necessary
to preincubate TNF with a TNFRI peptide to enable the binding
of the peptide to TNF prior to addition to cells. The data also
show that whereas TNFRI206–211 bound TNF, the scrambled
version that was devoid of inhibitory actions, did not bind.
Furthermore, hexamers of TNFRI from CRD1–CRD3, unlike
TNFRI206–211, did not prevent TNF from stimulating neutrophils
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to produce superoxide. This also demonstrates the speciﬁcity of
residues 198–211 in TNFRI in coupling TNF-p38 to the neu-
trophil respiratory burst function.
Anti-TNF biologics have revolutionised the treatment of
chronic inﬂammatory conditions such as rheumatoid arthritis1.
However, this form of therapy is associated with increased sus-
ceptibility to infection and cancer1–6. Furthermore, the FDA has
issued warnings against such use in paediatric patients between
the ages of 4–17 owing to increased risk of malignancy5,6.
Another approach in the treatment of chronic inﬂammation has
involved the targeting of the intracellular pathways used by the
TNFR. Although p38 inhibitors represent one of the most her-
alded form of therapies for the treatment of inﬂammation in
recent times, clinical trials with a range of unrelated pharmaco-
logical p38 inhibitors for the treatment of rheumatoid arthritis
and other chronic inﬂammatory conditions have shown poor
clinical outcomes with transient immunosuppressive effects,
associated with increased risk of severe infections, liver/brain/skin
toxicity and other adverse effects8,23,24. These disappointing
clinical data signal that systemic inhibition of p38 is an inap-
propriate form of treatment.
The p38 pathway plays a dual role in regulating the inﬂam-
matory response. Thus, blockade of the p38 pathway in murine
macrophages or human synovial cells not only caused a decrease
in the production of proinﬂammatory mediators such as MMP-
13, KC, TNF and IL-6, but also the anti-inﬂammatory IL-1025,26.
In addition, such blockade also resulted in a decrease in the
expression of the MAP kinase phosphatase, DUSP-125,26 that
inactivates active p38 and active JNK. Consequently, p38 activa-
tion also initiates a negative feedback mechanism that limits the
strength and duration of the function of this signalling pathway.
Previous studies have demonstrated that the p38-mediated reg-
ulation of IL-10 and DUSP-1 expression is mediated by the
downstream mitogen- and stress-activated kinases (MSK)1 and
MSK2, two of the kinases that phosphorylate the transcription
factors, CREB and ATF-1, that bind to the promoters of IL-10
and DUSP-1 and enhance their transcriptional activity27. Con-
sistent with its role in mediating an anti-inﬂammatory action, p38
inhibition in vivo was found to cause disease exacerbation and
prolonged the duration of disease in animal models of inﬂam-
matory diseases25,26. This is likely to be a key reason for the
failure of drugs that target p38 in clinical trials.
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The TNFRI peptides do not target p38 per se, unlike previously
described p38 inhibitors. The peptides only targeted TNF-
mediated activation of p38. Consequently, it did not affect
fMLF-stimulated respiratory burst in neutrophils and p38 acti-
vation. TNF binding to the TNF receptor was not affected by
TNFRI206–211, which also did not affect TNF-induced ERK1/
ERK2, JNK and NF-κB activation, unlike TNF-neutralising bio-
logics. These observations demonstrate that the TNFRI peptides
are a unique class of agents that have the capability to block the
actions of TNF that require p38, without inhibiting the p38
pathway in general, thus enabling the normal functioning of this
pathway when it is activated by other stimuli. Intriguing is the
ﬁnding that TNFR206–211 selectively blocks the ability of TNF to
stimulate p38 activation, most likely explaining its unique in vivo
effects in experimental inﬂammatory models.
Our work has illustrated that the TNFR peptide while capable
of binding TNF does not prevent the binding of TNF to TNFRI
but it selectively causes inhibition of p38 activation and associated
function. Given that the TNFR peptide sequence covers the
minimal region that is required for TNF to activate p38, it is likely
the peptide alters the dynamics of the TNF–TNFR interaction—
allowing not only TNF binding to TNFRI, but also the activation
of the other signalling molecules that the receptor normally
activates. This implies that other regions of TNFRI mediate the
activation of the other signalling molecules. While this interaction
is interesting, the mechanism leading to the selective inhibition
of p38 remains to be fully elucidated. Nevertheless, the data from
the current study illuminates a novel approach to block the TNF-
p38 signalling axis and treat inﬂammation. Another advantage of
the TNFRI peptides over current anti-TNF biologics is the ability
of the peptides to promote clearance of RSV from infected mice.
It has been reported that dsRNA from RSV induces the pro-
duction of inﬂammatory cytokines in bronchial epithelial cells via
a p38 and not NF-κB-dependent mechanism28. It is therefore
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likely that the peptide by inhibiting the TNF-TNFRI-p38 axis
prevents the development of a cytokine ‘storm’ and its wide range
of debilitating effects on leukocyte function, enabling leukocytes
to kill virus-infected cells effectively. In contrast, current anti-
TNF biologics may interfere with virus-clearance and promote
tissue damage. We have demonstrated that Ross River virus
(RRV)-infected mice treated with etanercept showed decreased
weight gain, higher viral titre in muscle, joints and blood, asso-
ciated with a greater degree of tissue damage and inﬂammatory
cell recruitment than untreated RRV-infected mice29. Thus, the
TNFRI peptides appear to have a number of advantages over
existing anti-TNF biologics and pharmacological p38 inhibitors.
Although we cannot rule out the possibility that the TNF receptor
biologics would not predispose the host to infections, it is less
likely that this would be an issue because of their target speciﬁcity.
We propose that the TNFRI peptides could be developed as
anti-TNF-p38 biologics for the treatment of inﬂammation. While
peptide therapeutics are associated with disadvantages such as
their susceptibility to proteolytic degradation in vivo and the need
for injection, a number of peptides are currently undergoing or
have completed phase 1, 2 or 3 clinical trials30. These include
KAI-9803 (Kai Pharmaceuticals), a selective protein kinase C δ
inhibitor peptide to reduce infarct size in subjects with ST ele-
vation myocardial infarction; KAI-4169, a peptide agonist of the
calcium sensing receptor for the treatment of secondary hyper-
parathyroidism; XG-102 (Xigen) (also known as AM-111 from
Auris Medical), a JNK-inhibiting peptide composed of D-amino
acids for the treatment of stroke, inﬂammation, severe inner ear
disorders and acute sensorineural hearing loss; the islet
neogenesis-associated protein (INGAP) peptide (Exsulin Cor-
poration) for islet beta cell neogenesis and improvement in gly-
cemic control in type 1 diabetic patients, and AZX100 (Capstone
Therapeutics), a peptide derived from HSP20 for the regulation of
smooth contraction and dermal scarring. Stability can be
increased by the use of D-amino acids as shown by XG-102 (AM-
111). Our in vitro data also show that D-TNFRI peptides
exhibited increased activity over the L-forms (Fig. 3h versus
Fig. 3j). Our ﬁnding also opens the possibility of developing
nonpeptidyl small molecules to block the TNF-p38 axis. The
feasibility of this approach is exempliﬁed by SB 247464, a non-
peptidyl small molecule reported to activate the G-CSF
receptor31.
In summary, we have identiﬁed an attractive approach to target
key pathways in treating inﬂammation associated with microbial-
or autoimmune-mediated immunopathogenesis. Selective target-
ing of discrete domains in TNFR and of key signalling pathways
within the spectrum activated by TNFR has major advantages
over the global inhibition of TNF–receptor interaction or the
systemic inhibition of a speciﬁc signalling molecule and it is
tempting to speculate that the concept derived from our ﬁndings
will have a wider implication in other ligand–receptor
interaction-based therapeutic intervention. Peptides developed in
this manner could also serve as valuable tools for elucidating the
mechanism of disease pathogenesis in vivo.
Methods
Mice. Female BALB/c mice, 6–8 weeks of age, were purchased from the Adelaide
University Laboratory Animal Services, Adelaide, SA, Australia and from the
Animal Resource Centre, Perth, WA, Australia. These were housed on a 12-h light/
dark cycle with ad libitum access to food and water in the Women’s and Children’s
Hospital Animal House, Adelaide, SA, Australia and the animal facility at the
University of Canberra, ACT, Australia. The study was approved by the Women’s
and Children’s Hospital Animal Ethics Committee, the University of Adelaide
Animal Ethics Committee (project number AEC 782a/2/2011) and the University
of Canberra Animal Ethics Committee (project number CEAE 08–13). The
research was conducted according to the Animal Welfare Guidelines of the
National Health and Medical Research Council of Australia.
Neutrophils and cell lines. The study was approved by the CYWHS Human
Ethics Committee (project number HREC 595/12/10). Neutrophils were prepared
from peripheral blood of healthy donors, who had given informed consent, by a
rapid single-step technique32. Blood was layered on to Hypaque-Ficoll (Pharmacia
Biotech., Uppsala, Sweden), d= 1.114, and centrifuged at 600 × g for 20–30 min.
After centrifugation, the leukocytes resolved into two bands and the neutrophils
were harvested from the second band. The preparations of neutrophils were rou-
tinely of >99% viability and >98% purity. These were either used as cells in sus-
pension or as adhered neutrophils by adding the cells to plasma-coated plates as
previously described33. The 70Z/3 pre-B cell line, kindly provided by Dr. W.
Langdon, University of Western Australia, Perth, Australia, are mouse pre-B
lymphocytes which lack binding sites for human TNF and are non-responsive to
the cytokine18,19. The cells were maintained in RPMI 1640 medium with 4.5 g/L
glucose, 2 mM L-glutamine, 50 mM 2-mercaptoethanol and 10% FCS in an
atmosphere of 95% air and 5% CO2. The monocytic cell line, MonoMac 6 was
kindly provided by Dr. H.W.L. Ziegler-Heitbrock (Institute of Clinical Chemistry
and Pathobiochemistry, Klinikum rechts der Isar, Technische Universitat,
Munchen, Germany) and maintained in RPMI 1640 supplemented with 10% heat-
inactivated foetal calf serum, 1 mM pyruvate, glutamine and antibiotics. A mouse
ﬁbroblastic ﬁbrosarcoma cell line WEHI-164, clone 13 (from the ATCC) was
obtained from Dr. Geeta Chauhdri (John Curtain School of Medical Research,
Australian National University, Canberra, Australia). The cells were maintained in
RPMI-1640 medium as above and the cells were detached with 0.25% trypsin
EDTA. HEK 293T cells were maintained in DMEM, supplemented with 10% foetal
calf serum. Cells, stably transfected with pRK5-TRAF2-FLAG, pRK5-TRAF287–501-
FLAG (Dr. V. Dixit, Genentech Inc., South San Francisco), or an empty plasmid
(pRK5, BD Pharmingen/Biosciences, North Ryde, NSW, Australia) using Lipo-
fectAMINE 2000 (Life Technologies Pty Ltd, Mulgrave, VIC, Australia), were
obtained from Dr. P. Xia, Centenary Institute of Cancer Medicine and Cell Biology,
Sydney, Australia. The promyelotic leukaemia HL-60 cells (ATCC # CCL-240;
batch # F-13704) were cultured in RPMI-1640 supplemented with antibiotics, L-
glutamine and 10% heat-inactivated foetal calf serum. Twelve-well culture plates
were seeded with 1–2 × 106/ml HL-60s per well and the media supplemented with
1.25% v/v DMSO and allowed to differentiate for 4–5 days34, before treatment with
TNF/peptides.
TNF and TNF receptors. Human recombinant TNF was a gift from Dr. G.R. Adolf
(Ernst-Boehinger Ingelheim Institut, Vienna, Austria) and also purchased from
ProSpec-Tany TechnoGene (Rehovot, Israel). Recombinant mouse TNFα was
purchased from Gibco (Frederick, MD). TNF stock solution was stored at −20 °C
until required. Fresh dilutions of TNF were prepared in HBSS just prior to use.
Human recombinant soluble TNFRI [rHusTNFRI (22–211), prepared as a chimeric
protein with the 6x histidine tagged Fc portion part of human IgG1] was purchased
from Prospec-Tany TechnoGene (Rehovot, Israel).
TNF and TNFRI peptides. TNF70–80 and its control (GGDPGIVTH) were syn-
thesised by Auspep Pty Ltd, (Tullamarine, VIC, Australia) and Genscript Biotech
(Piscataway, NJ, USA). While it is difﬁcult to directly equate the TNF activity to
TNF70–80 because of the lack of tumour cell cytotoxicity of this peptide, compar-
isons on their ability to stimulate nitric oxide production in macrophage have been
used. These show that 5.0 μg/ml of TNF70–80 equates to 1000 U/ml of TNF9. The
sequence from the natural TNF-α was modiﬁed by substitution of isoleucine for
leucine at residue 79. The modiﬁcation extended the serum half-life of the peptide
to >90 min and increased water solubility. Fresh dilutions of the peptide were
prepared daily in HBSS or HBSS with 1% BSA. The His-tagged M4 (HM4) ΔHM4
(LKPGTT) was purchased from Auspep Pty Ltd (Tullamarine, VIC, Australia).
TNF132–150 (LSAEINRPDYLDFAESGQV), TNFRI209–211 peptide (GTT); scram-
bled control (TGT) and TNFRI206–211 (EDSGTT), scrambled control (GEDTST),
TNF198–211 (GIENVKGTEDSGTT) D-forms, as well as peptides of sequences in
CRD of TNFRI: TNFRI77–82 from CRD1 (QDTDCR), TNFRI90–95 from CRD2
(TASENH) and TNFRI129–134 from CRD3 (KNQYRH) were purchased from
GenScript Biotech (Piscataway, NJ, USA). Peptides were puriﬁed by high-
performance liquid chromatography (HPLC) and analysed by mass spectrometry
to be >85% pure. Peptides were stored at −20 °C and solutions were made in HBSS
or RPMI prior to use.
Preparation of cell lysates. The cells were lysed in 200 μl of buffer A (20 mM
HEPES, pH 7.4, 0.5% (v/v) Nonidet P-40, 100 mM NaCl, 1 mM EDTA, 2 mM
Na3VO4, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride and 10 μg/ml
leupeptin, aprotonin, pepstatin A and benzamidine) for 2 h at 4 °C with constant
mixing35. After centrifugation (12,000 × g for 5 min), the supernatants were col-
lected and the protein content of the lysates was determined by Lowry’s method of
protein determination. Samples were stored at −70 °C until assayed. For western
blot analysis, samples were mixed with Laemmli buffer and boiled before being
stored for subsequent electrophoresis.
Immunoprecipitation of signalling molecules. Lysates containing equal amounts
of protein (0.5–1 mg) were pre-cleared with 15 μl/sample protein A sepharose
(Pharmacia, NJ, USA) (1:1 slurry of sepharose in 20 mM Tris/HCL, pH 7.4) (4 °C)
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before being incubated with rabbit polyclonal anti-mouse p38α antibody (sc-535,
Santa Cruz Biotech, Santa Cruz, CA) (3 μg/sample). After mixing for 2 h (4 °C), the
immune complexes were precipitated by the addition of 20 μl/sample protein A
sepharose. The immunoprecipitates were collected by centrifugation (16,000 × g for
15 s) and washed once with buffer A (4 °C), once with buffer B (10 mM Tris/HCl,
pH 7.6, 100 mM NaCl, 1 mM EDTA and 100 μM Na2VO4) and once with assay
buffer (20 mM Hepes, pH 7.2, 20 mM β-glycerophosphate, 3.8 mM p-nitrophenyl
phosphate, 10 mMMgCl2, 1 mM dithiothreitol, 50 μMNa3VO4 and 20 μMATP)35.
The assay buffer was removed following a further centrifugation in preparation for
kinase activity assay.
Western blotting for MAP kinases and IκB-α. Western blot analysis was con-
ducted as described previously35. Brieﬂy, equal amounts of denatured protein from
each lysate were separated by 10% SDS polyacrylamide gels. The proteins were
electrophoretically transferred to nitrocellulose membranes using a Bio-Rad Trans-
Blot Turbo (Hercules, CA, USA). The amounts of phosphorylated p38, ERK1/
ERK2, JNK and levels of IκB-α were detected using rabbit polyclonal anti-p-p38
(Thr 180/Tyr 182)-R (sc-17852-R), mouse monoclonal anti-p-ERK1/2 (pT202/
pY204.22A) (sc-136521), mouse monoclonal anti-p-JNK (G-7) (sc-6254) and
rabbit polyclonal anti-IκBα (C-21)(sc-371) antibody (Santa Cruz Biotech, Dallas,
TX, USA), respectively. These antibodies were used at 1:1000 dilution. Immune
complexes were visualised by enhanced chemiluminescence. Ponceau S (0.1% in
5% acetic acid) staining was performed to verify total protein loading. Some blots
were stripped and re-probed with rabbit polyclonal anti-p38 (C-20) (sc-535, Santa
Cruz, used at 1:1000) antibody to conﬁrm equal loading.
Assays for p38 activity. p38 activity was determined, after immunoprecipitation,
as described using myelin basic protein (MPB) as a substrate for the kinase in the
presence of 32P-ATP35. We have demonstrated that p38 immunoprecipitates do
not contain ERK1/ERK235. Brieﬂy, 30 μl of assay buffer (30 °C) containing 10 μCi
of γ32P-ATP, 3.8 mM p-nitrophenyl phosphate and 15 μg of myelin basic protein
was added to each sample. The samples were then incubated in a water bath at 30 °
C. After 15 min, the assay was terminated by the addition of Laemmli buffer and
boiling the samples (100 °C) for 5 min, Following fractionation (12% SDS poly-
acrylamide gels), the amount of 32P-MBP was determined using an Instant Imager
(Packard Instruments, Canberra, Australia).
Construction of TNFR1 mutants. The hTNFRI plasmid (pADB-TR55) was kindly
provided by Dr. M. Kronke19 (University of Cologne, Koln, Germany). The signal
sequence from the TNFR1 cDNA was isolated by PCR and cloned, via an NheI site
incorporated into the 5′ primer and a KpnI site in the 3′ primer, into the
expression vector pcDNA3.1 (ThermoFisher Scientiﬁc, Scoresby, VIC, Australia).
A double-stranded oligonucleotide encoding His 6-tag, with KpnI and BamHI
sticky ends, in frame with the signal peptide, was cloned downstream of the signal
sequence. The transmembrane and cytoplasmic domains of the TNF receptor were
also isolated by PCR and cloned, via a 3′ BstXI site and a 5′ XhoI site incorporated
into the PCR primers, 3′ of the hexahistidine sequence. This construct was
designated cDNA3sigHIScTNF (WT). The mutants designated M1 and M4 (Fig. 3)
which lacked the ﬁrst and all four cysteine-rich domains, respectively, were isolated
using the restriction enzyme sites incorporated into the primers, cloned between
the BamHI and BstXI sites of the pcDNA3sigHIScTNF, such that the reading was
contiguous with the signal, 6x His and transmembrane/cytoplasmic coding
sequences.
Binding of TNF70–80 to recombinant human soluble TNFRI. Microtitre plates
were coated with 100 μl/well of 3 μg/ml rHusTNFRI (ProSpec-Tany TechnoGene
Ltd, Rehovot, Isreal) in 18MQ-cm H2O overnight at 4 °C and blocked with 1% BSA
and 0.05% Tween-20 in PBS for 1 h at 4 °C. Aliquot of 10 μM of biotin-labelled
TNF70–80 (Auspep Pty, Ltd., Tullamarine, VIC, Australia) plus various con-
centrations of unlabelled TNF70–80 or control peptide were added to each well and
incubated for 3 h at 4 °C. The wells were washed four times with wash buffer (PBS
containing 0.05% Tween-20) and the plates were incubated with 100 μl/well of
poly-horseradish peroxidase streptavidin conjugate (1/6000 dilution in 1% BSA
and 0.05% Tween-20 in PBS) for 45 min at 4 °C. Wells were washed four times with
wash buffer and bound enzyme detected by the addition of 3′,3′,5′,5′-tetra-
methylbenzidine (TMB) substrate (Sigma-Aldrich, Castle Hill, NSW, Australia).
Absorbance was measured using dual ﬁlter at 570/450 nm on a Dynatech MR700
Plate Reader (Guernsey, Channel Islands).
TNF or TNF70–80 binding to TNFRI peptides. Depending on the experiment,
microtitre plates were coated with 100 μl/well of either 3 μg/ml TNFRI198–211 in
MilliQ water or TNFRI206–211 or the corresponding scrambled peptide in
carbonate-bicarbonate buffer (pH 9.6) overnight at 4 °C and blocked with 1% BSA
and 0.05% Tween-20 in PBS for 1 h at 4 °C. In the TNFRI198–211-coated plates,
various concentrations of biotinylated TNF70–80 or control peptide were added to
triplicate wells and incubated for 3 h at 4 °C. In the TNFRI206–211/scrambled
peptide-coated plates, 50 U of TNF was added to triplicate wells, followed by
washing with wash buffer (PBS/0.05% Tween-20) and then incubation with 50 μl of
1.5 μg/ml biotinylated monoclonal anti-TNF antibody (clone 2TNF-H33,
ThermoScientiﬁc, Waltham, MA, USA). The wells from all plates were washed four
times with wash buffer, then incubated with 100 μl/well of poly-horseradish per-
oxidase streptavidin conjugate (1/6000 dilution in 1% BSA and 0.05% Tween-20 in
PBS) (ThermoScientiﬁc, Waltham, MA, USA) for 45 min at 4 °C. Wells were
washed four times with wash buffer and bound enzyme detected by the addition of
TMB substrate (Sigma-Aldrich, Castle Hill, NSW, Australia). Absorbance was
measured using dual ﬁlter at 570/450 nm on a Dynatech MR700 Plate Reader
(Guernsey, Channel Islands).
TNF binding to soluble TNFRI in the presence of TNFRI206–211. TNF binding to
sTNFRI was assayed by a modiﬁcation of the Davis et al.36 method. Using a 96-well
high-binding plate, 100 μl of 0.25 μg/ml sTNFRI in 0.05M carbonate-bicarbonate
buffer (pH 9.6) was incubated overnight at room temperature. The plate was
washed three times with wash solution (PBS+ 1% Tween-20) for 5 min each and
then blocked for 1 h at 37 °C with 100 μl of PBS+ 10% BSA. Following another
three washes, the plate was loaded with 50 μl of either assay solution (PBS+ 4%
BSA), or 500 U TNF and/or 10 mM TNFRI206–211 (pre-incubated for 10 min
together or separately) in assay solution and incubated for 2 h at room temperature.
After three washes, all wells were loaded with 50 μl of 1.5 µg/ml biotinylated
monoclonal anti-TNF antibody (Clone 2TNF-H33, ThermoScientiﬁc, Waltham,
MA, USA) for 60 min, washed three times, then incubated with 50 μl of poly-HRP
streptavidin conjugate (1/6000 in assay solution) for 30 min. After washing three
times, 50 μl of TMB substrate was added and incubated for 15 min, followed by
addition of 50 μl 0.5 M sulphuric acid. Absorbance was measured at 570/450 nm.
Inhibition of TNF-induced p38 activation by TNFRI206–211. In these experiments,
either 100 µl of 200 U/ml human TNF was treated with 100 µl of 4 mM of
TNFRI206–211 or 500 µl of 100 ng/ml mouse TNF was treated with 500 µl of 8 mM
of the TNFRI206–211 for 15 min at 37 °C, then added to human or mouse cells (2 ×
106) in a ﬁnal volume of 1 ml or 5 ml, respectively. Following incubation at 37 °C
for 15 min (for p38, ERK and IκB-α) or 30 min (for JNK), cell lysates were prepared
for western blot analyses. Adherent neutrophils were required for ensuring ERK
activation by TNF. Similarly, HL-60 cell-derived neutrophils were required for
inducing JNK activation by TNF.
Transfection of pre-B cells with hTNFRI or mutant receptor DNA. 70Z/3 cells
were plated onto 10 cm plates at 4 × 107 cells in 15 ml culture medium. Before
performing transient transfection, plasmid DNA (20 μg in 1 ml of RPMI 1640) was
mixed with LipofectAMINE 2000 (Life Technologies Pty Ltd, Mulgrave, VIC,
Australia) (60 μl in 1 ml of RPMI 1640) and the mixture was left at room tem-
perature for 20 min. The mixture was directly added to the cells and incubated for
24 h. The cells were washed twice with HBSS before use.
Cellular functions. Neutrophil superoxide production was measured by an indirect
assay involving the reduction of the lucigenin, (9, 9′-bis N-methyl-acridinium
nitrate) (Sigma-Aldrich, Castle Hill, NSW, Australia) and measuring the light
output by lucigenin-dependant chemiluminescence37. Neutrophils (5 × 105) were
incubated with TNF70–80, TNF or other stimuli that had previously been pre-
incubated in the absence or presence of receptor peptides for 20 min. After incu-
bation, 500 μl of lucigenin (250 μM, ﬁnal) was added and the ﬁnal volume was
adjusted to 1 ml. The cells were placed in luminometer (Autolumat Plus Model LB
953, Berthold Technologies, Bundoora, VIC, Australia) and the resulting chemi-
luminescence (in relative light units, RLU) measured. The results are expressed as
maximal/peak rate of chemiluminescence produced unless speciﬁed otherwise. CR3
expression on neutrophils was measured by ﬂow cytometry using anti-CD11b
antibodies33. Neutrophils (1 × 106) were incubated for 30 min with TNF that had
previously been pre-incubated in the absence or presence of receptor peptides for
20 min. After treatment, 2 μl of PE-labelled mouse IgG2a isotype control (Clone
X39) or PE-labelled monoclonal anti-CD11b antibody (Clone D12) (both from BD
Biosciences, North Ryde, NSW, Australia) was added to neutrophils in 200 μl of
Isoton II (BD Biosciences) supplemented with 0.1% (w/v) BSA. After 30 min the
cells were washed, ﬁxed with formaldehyde (0.1%) and analysed on a FACScan
(BD Biosciences, North Ryde, NSW, Australia). Cytokine (IL-1β and IL-8) mRNA
productions were measured by quantitative RT-PCR. Brieﬂy, total RNA was
extracted from 1 × 106 neutrophils using the TRIzol reagent (Life Technologies
Australia Pty, Mulgrave, VIC, Australia) according to the manufacturer’s instruc-
tions. RNA was converted to cDNA using iScript cDNA synthesis kit (Bio-rad,
Hercules, CA, USA). The cDNA was then ampliﬁed in triplicate reactions with iQ
SYBR Green supermix (Bio-rad, Hercules, CA, USA) and 500 nM of each primer
pair for IL-1β (Forward primer 5′–3′: TCA TTG CTC AAG TGT CTG AAG C;
Reverse primer 5′–3′: TCC TGG AAG GAG CAC TTC AT) and IL-8 (Forward
primer 5′–3′: TCT GTG TGA AGG TGC AGT TTT G; Reverse primer 5′–3′: AAT
TTC TGT GTT GGC GCA GT) and the house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) using iQ5 system with v.3.1 software.
In vivo inﬂammation models. Four models of in vivo inﬂammation reactions were
used to assess the anti-inﬂammatory activity of the TNFRI peptides. Female, 6–8-
week-old BALB/c mice were utilised in these models: (i) lipopolysaccharide-
induced peritoneal inﬂammation38, (ii) carrageenan-induced paw inﬂammation,
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(iii) antigen-induced delayed hypersensitivity38, (iv) RSV-induced lung inﬂam-
mation39. Inﬂammation was gauged by either one or a combination of the fol-
lowing: tissue changes, cellular inﬁltration and cytokine levels. Animals were
allocated randomly to the various groups. The studies were sufﬁciently powered
based on power calculation at α of 0.05 and β of 0.2.
Lipopolysaccharide-induced peritoneal inﬂammation. Mice were injected
intraperitoneally (i.p.) with 50 µg of LPS (Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia) or HBSS40. At 24 h, the animals were killed and cellular inﬁltrates in the
peritoneal exudates examined in Giemsa-stained smears. The total leukocyte and
neutrophil number in the peritoneal exudates was enumerated using a hemocyt-
ometer chamber and the neutrophils from a differential count of the stained
smears.
Delayed-type hypersensitivity. The delayed-type hypersensitivity (DTH)
response was conducted by injecting mice with sheep red blood cells (SRBC) (100
µl of 10% haematocrit) (Applied Biological Products, Aldinga Beach, SA, Australia)
subcutaneously in the back38. Six days later, mice were challenged in the right hind
footpad with 25 μl of 40% suspension of SRBC. The DTH response was determined
24 h post challenge by measuring the footpad thickness of the unchallenged vs.
SRBC-injected footpads with a caliper on a micrometre screw gauge. The
inﬂammatory response was expressed as the difference in thickness (mm) between
the unchallenged and antigen-challenged footpads.
Carrageenan-induced paw inﬂammation. Carrageenan-induced paw inﬂamma-
tion was induced by inoculating mice with 1 ml/kg of a 1% solution of carrageenan
type IV (w/v) into the right hind footpad39. The swelling/inﬂammation was
assessed 24 h later by comparing the thickness between the unchallenged vs. car-
rageenan challenged footpads as described above.
RSV-induced inﬂammatory mouse model. BALB/c mice were housed in
microisolator cages with their own food and water supply and were treated
intranasally (i.n.) with three doses of 100 mg/kg of TNFRI206–211 or the control
scrambled peptide administered on day −1, 1 and 3. On day 0, mice were infected
i.n. with 1 × 106 plaque forming units of RSV A2. Prior to all intranasal treatments
and infections mice were anaesthetised i.p. with Alfaxan. On day 5, mice were
killed.
Respiratory syncytial virus propagation. The RSV strain A2 was propagated in
Vero E6 cells. An 80% conﬂuent T150 ﬂask of Vero E6 cells was infected with RSV
at a multiplicity of infection of 0.5 in a total volume of 6 ml of DMEM. Cells were
infected for 2 h at 37 °C and 5% CO2. After 2 h, 8 ml of DMEM with 5% foetal
bovine serum was added and ﬂasks incubated at 37 °C and 5% CO2 for ~2–3 days
or until 25–50% syncytia formation was observed. At harvest time all but 2 ml of
media was removed and cells were scraped from the ﬂask, transferred to a 50 ml
tube and incubated on ice for 10 min. Cells were sonicated for 5 s at 25W, three
times, with a 2 min incubation on ice between each sonication. Cell debris was
removed by centrifugation at 350 × g for 7 min at 4 °C and the supernatant con-
taining the virus stored at −80 °C. The Vero E6 cells used were VERO 1008 (Ver
76, clone E6) originally sourced from ATCC (ATCC CRL-1586). Cells were rou-
tinely tested for mycoplasma by using the LookOut Mycoplasma PCR detection kit
(Sigma-Aldrich cat no. MP0035)
Bronchoalveolar lavage and cytospin. After killing, the left lung was ligated at the
left main branch of the trachea using surgical thread, and the right lung lavaged
twice with 0.5 ml PBS. BAL ﬂuid was centrifuged at room temperature at 350 × g
for 5 min and the supernatant collected and stored at −80 °C. The cell pellets were
lysed with BD PharmLyse Lysing Buffer, washed with PBS and resuspended in a
small volume of PBS. Total BAL cells were counted using a hemocytometer. Cells
were centrifuged onto glass slides (Menzel-Glaser, Germany) using a cytospin
(Rotoﬁx 32 Hettich, Germany), ﬁxed in methanol and stained with modiﬁed
Giemsa. Cell differential percentages were determined by light microscopy.
Histological analysis. A lobe of the non-lavaged lung was ﬁxed in 10% formalin,
embedded in parafﬁn and 3 μm sections stained with hematoxylin & eosin (H&E).
Slides were scored by an observer blinded to the treatment groups. The severity of
inﬂammation was quantitated on a 0–3 scale with uninfected control mice deﬁned
as 0, and 3 being the maximum inﬂammation score41.
Mouse cytokine analysis. IL-4 and IFN-γ cytokine concentration was determined
from the ﬁrst BAL wash by ELISA kits from BD Biosciences and R&D systems,
respectively, according to the manufacturer’s instructions.
Virus titres. RSV from a lobe of the non-lavaged lung was determined by
immunostaining. The lung was homogenised in PBS (containing penicillin,
streptomycin and neomycin) using the TissueLyser II (Qiagen, Chadstone Centre,
VIC, Australia), centrifuged at 1700 × g and the supernatant collected. Twenty-
four-well tissue culture plates were seeded with Vero E6 cells in DMEM containing
5% FBS incubated overnight at 37 °C and 5% CO2 to obtain 80–90% conﬂuency.
Monolayers were washed with HBSS and serial dilutions of the lung supernatants,
in DMEM, were added to the cell monolayers in quadruplicate. Plates were
incubated at 37 °C in 5% CO2 for 1 h. The wells were overlaid with 1 ml of 2%
methylcellulose media (DMEM containing antibiotics, 2% FBS, 20% HBSS and 2%
methylcellulose (Methocel®MC, Sigma-Aldrich, Castle Hill, NSW, Australia) and
incubated at 37 °C and 5% CO2. After 6 days, the overlay was removed and
monolayers ﬁxed with 1 ml of ice-cold acetone:methanol (60:40) for 10 min. Plates
were air dried at room temperature and blocked in 5% skim milk powder diluted in
PBS for 30 min at room temperature. Primary RSV monoclonal anti-F antibody
131–2A was added to wells for 2 h, followed by goat anti-mouse IgG-alkaline
phosphatase secondary antibody for 1 h. All antibodies were diluted 1:1000 in 5%
block and incubated at 37 °C. After each antibody, plates were washed three times
with PBS containing 0.5% Tween-20. The assay was developed using the Alkaline
Phosphatase Substrate Kit II (Vector Laboratories, USA) as per manufacturer’s
protocol.
Statistics and analysis. Results are presented as mean ± standard error of the
mean (SEM) unless stated otherwise. The F-test or Brown–Forsythe test was used
to examine homogeneity or equality of variance. For parametric data, differences
were analysed by either one or two-tailed t-test, one sample t-test or one-way
ANOVA followed by Dunnett’s multiple comparison test. For non-parametric
data, a Mann–Whitney analysis (one or two tailed) (comparison between two
groups), a Fischer exact test (one tail) or, either a Friedman test or a
Kruskal–Wallis analysis was performed, followed by Dunn’s multiple comparison
test. Differences were considered statistically signiﬁcant when p < 0.05. Statistical
analyses were performed on GraphPad Prism 5 software.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and from the authors on request.
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